Neurocrine Biosciences, Inc. (NBIX) Posts Q1 Loss of 17c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Neurocrine Bio. (NBIX) PT Trimmed at Jeffereis, 'Buy' Maintained
May 1, 2014 8:03 AM EDTJefferies analyst Thomas Wei trimmed his price target on Neurocrine Bio. (NASDAQ: NBIX) to $21.00 (from $23.00) but maintained a Buy rating following the company's Q1 update.
Wei comments, "On its 1Q14 call, NBIX focused on its upcoming FDA meeting and subsequent initiation... More
